Racial differences in predictive value of the 21-gene recurrence score assay: a population-based study using the SEER database.

ABSTRACT:

Purpose

The 21-gene recurrence score (RS) assay is currently used for predicting chemotherapeutic benefits for hormone receptor-positive (HR +) early-stage breast cancer patients without consideration regarding racial differences in that predictive value. This study aimed at demonstrating racial differences in the predictive values of the 21-gene RS assay.

Methods

The study cohort was selected from the Surveillance, Epidemiology, and End Results (SEER) database. Breast cancer-specific mortality (BCSM) was compared between patients who received chemotherapy (the "CTx group") and those who did not (the "no CTx group") to estimate the predictive value of the assay. This comparison was repeated for each racial group.

Results

Among 88,498 T1 - 2N0 HR + breast cancer patien

SUBMITTER: Jung J 

PROVIDER: S-EPMC9385768 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature